SCHEMBL26423975

SCHEMBL26423975

c1ccc2cc(-c3ccc(N(c4ccc(-c5cc6ccccc6cn5)cc4)c4ccc5cc6c(cc5c4)sc4ccccc46)cc3)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ AKT1 P31749 2/20 0.33
▸ CYP1A2 P05177 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ CASP3 P42574 1/20 0.31
▸ SENP7 Q9BQF6 1/20 0.31
▸ IDO1 P14902 1/20 0.30
▸ TDO2 P48775 1/20 0.30
▸ S1PR1 P21453 1/20 0.30
▸ CYP17A1 P05093 1/20 0.30
▸ CYP19A1 P11511 1/20 0.30
▸ CYP11B1 P15538 1/20 0.30
▸ CYP11B2 P19099 1/20 0.30
▸ GABRP O00591 1/20 0.30
▸ GABRD O14764 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26423979 1.00 NPC1 (0.38) NPC1RAB9AAKT1CYP1A2ALDH1A1
SCHEMBL26423972 0.93 NPC1 (0.40) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL25663240 0.87 ALDH1A1 (0.35) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL24057707 0.86 GABRP (0.36) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL25663242 0.86 RAB9A (0.34) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL26834175 0.85 RAB9A (0.38) NPC1RAB9AAKT1CYP1A2ALDH1A1
SCHEMBL26833747 0.85 IDO1 (0.34) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL26833755 0.85 GABRP (0.35) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL24055542 0.85 GABRP (0.37) NPC1RAB9ACYP1A2ALDH1A1CYP2C9
SCHEMBL24055536 0.85 IDO1 (0.38) NPC1RAB9ACYP1A2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-04-27 — — US disclosed
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL OCIAD2, OCIAD1, AZI2 NPC1 2884/4885RAB9A 2686/4885AKT1 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback